Marksans Pharma to acquire 100 percent stake in Germany's ABCnow GmbH
MARKSANS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.8 pts more than Nifty Microcap 250 and 1.6 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Marksans Pharma has signed a definitive agreement to acquire 100% of German pharma distributor ABCnow GmbH for about EUR 892,384 in cash. ABCnow markets OTC products in Germany with revenue of EUR 227,234 in 2025 and EUR 510,216 in 2024. The deal is not a related party transaction, needs no regulatory approval, and is expected to close by July 31, 2026. The acquisition gives Marksans a direct front-end to sell its products manufactured in India, UK and USA across the EU market.
Expands Marksans Pharma's direct owned presence in European markets through German sales and distribution, supporting long-term EU growth.